Autotaxin (ATX) is an enzyme responsible for the production of lysophosphatidic acid (LPA), which plays a role in the pathogenesis of systemic sclerosis (SSc). Researchers from Mitsubishi Tanabe Pharma Corp. and colleagues have reported on the preclinical evaluation of MT-5562, a novel oral ATX inhibitor, as a therapeutic option for SSc.
Enochian Biosciences Inc. is on track to file an IND application for its innovative cancer platform around the early part or middle of next year. If successful, that would allow clinical trials to begin in the first half of next year.
At the recent American Transplant Congress, researchers from McGill University presented the discovery and preclinical evaluation of a novel retinoic acid receptor-related orphan receptor γt (RORγt) inhibitor, TF-S14, being developed as a potential therapy to delay skin allograft rejection.
Research led by Duke University and the German Center for Diabetes Research shows the glucose-dependent insulinotropic polypeptide (GIP) receptor plays an essential role in the action of the type 2 diabetes drug Mounjaro (tirzepatide; Eli Lilly and Co.) in human pancreatic islets.
A nutritional supplement to reduce the effects of aging might not be a pill of eternal youth, but it could reduce many of the problems of getting old while maintaining good health. The first step to achieve this is included in a study led by scientists from Columbia University. They have set their sights on the amino acid taurine.
Additional early-stage research and drug discovery news in brief, from: Karolinska Development, Tonix Pharmaceuticals, Transcode Therapeutics, Umecrine Cognition, Vycellix.
Novartis AG has identified diaminocyclopentylpyridine derivatives acting as proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors and thus reported to be useful for the treatment of hypercholesterolemia, hyperlipidemia, hypertriglyceridemia, sitosterolemia, vascular inflammation, atherosclerosis, peripheral vascular and coronary heart disease, among others.
Alchemedicine Inc. has prepared and tested new angiotensin AT1 receptor (AGTR1) antagonists reported to be useful for the treatment of cancer, hypertension, glaucoma and renal disorders.
Research at Seoul National University has led to the identification of thiourea compounds acting as nuclear receptor RORα (RORA) agonists reported to be useful for the treatment of inflammation and metabolic diseases.
An Agios Pharmaceuticals Inc. patent describes branched-chain-amino-acid aminotransferase, mitochondrial (BCAT2) inhibitors reported to be useful for the treatment of isovaleric acidemia, maple syrup urine disease, methylmalonic acidemia and propionic acidemia.
RSS
